Unknown

Dataset Information

0

Brentuximab Vedotin in CD30+ Lymphomas.

ABSTRACT: Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedotin has significant clinical activity in patients with relapsed or refractory cHL and relapsed or refractory ALCL, and has the potential to represent a significant advance in modern oncology.

SUBMITTER: Perini GF 

PROVIDER: S-EPMC3873074 | biostudies-other | 2013

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Brentuximab Vedotin in CD30+ Lymphomas.

Perini Guilherme Fleury GF   Pro Barbara B  

Biologics in therapy 20130301

Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedoti  ...[more]

Similar Datasets

Unknown Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
| S-EPMC5946765 | biostudies-literature
Unknown Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
| S-EPMC7102329 | biostudies-literature
Unknown Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
| S-EPMC5042201 | biostudies-literature
Unknown Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
| S-EPMC3994656 | biostudies-literature
Unknown Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
| S-EPMC8168499 | biostudies-literature
Unknown Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
| S-EPMC4171358 | biostudies-literature
Unknown Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
| S-EPMC5574006 | biostudies-literature
Unknown CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin.
| S-EPMC8362802 | biostudies-literature
Clinical Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
| 2141097 | ecrin-mdr-crc
Unknown CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.
| S-EPMC3744990 | biostudies-literature